Trial Profile
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Japanese Patients With Advanced Solid Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Capivasertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 09 Nov 2015 Preliminary results from CTPs 700060691 and 700198780 presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015
- 01 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Apr 2013 Results will be presented at AACR, according to an Astex Pharmaceuticals media release.